Bladder cancer is the seventh most common cancer worldwide. Urothelial carcinoma (formerly known as transitional cell carcinoma, TCC) comprises the majority of bladder cancers, accounting for more than 90%. In general, TCC is grouped into high- or low-grade (HG- or LG) lesions, based on their genetic profile and clinical behavior. The majority of bladder primary TCCs are LG (grades I and II) noninvasive (NI, pathologic stage pTa) papillary lesions. TCC is associated with a high rate of recurrence (75% after 5 years), and a distinct rate (10%–30%) of progression to HG lesions (grade III), carcinoma in situ, or invasive (IN, pT1). The UroVysion Bladder Cancer Kit (UroVysion Kit) is a US Food and Drug Administration-approved fluorescence in situ hybridization (FISH) probe set for use in the detection of recurrent urothelial carcinoma and in patients with hematuria. It is a multi-target multi-color assay designed to detect aneuploidies for chromosomes 3, 7, 17, and loss of the 9p21 locus in urine specimens. In this study we applied the UroVysion test on freshly isolated interphase nuclei and paraffin-embedded tissue from 22 TCCs (9 HGIN, 3 HGNI, 1 LGIN, 9 LGNI), in order to compare numerical aberrations in the two cell samples from the same tumor. 100 morphologically abnormal nuclei were considered for each sample in both tests, recording hybridization signals corresponding to each probe. The signals were divided according to loss (number of signals/cell < 2), disomy (number of signals/cell = 2), and gain (number of signals/cell > 3). Although the number of samples is low, we observed a general heterogeneity in the copy number changes, also among samples with the same histotype and, surprisingly, within the same sample comparing the two tests carried out. In particular, in the HGIN and LGNI tumors we found differences in copy numbers of chromosomes 3, 7, and 17 (p < 0.01) in 67%–89% of samples; for the 9p21 locus the differences were less significant. Our data provide further evidence for the intra-tumor heterogeneity present in different subpopulations of the same tumor, with interesting insights for diagnostic purposes.
Bentivegna, A., Panzeri, E., Conconi, D., Redaelli, S., Baronchelli, S., Viganò, P., et al. (2010). UroVysion Multiprobe FISH on transitional cell carcinoma of the urinary bladder: comparative analysis on fresh isolated interphasic nuclei and paraffin-embedded tissue. CANCER GENETICS AND CYTOGENETICS, 203(1), 79-79.
UroVysion Multiprobe FISH on transitional cell carcinoma of the urinary bladder: comparative analysis on fresh isolated interphasic nuclei and paraffin-embedded tissue
BENTIVEGNA, ANGELA;PANZERI, ELENA;CONCONI, DONATELLA;REDAELLI, SERENA;BARONCHELLI, SIMONA;DALPRA', LEDA
2010
Abstract
Bladder cancer is the seventh most common cancer worldwide. Urothelial carcinoma (formerly known as transitional cell carcinoma, TCC) comprises the majority of bladder cancers, accounting for more than 90%. In general, TCC is grouped into high- or low-grade (HG- or LG) lesions, based on their genetic profile and clinical behavior. The majority of bladder primary TCCs are LG (grades I and II) noninvasive (NI, pathologic stage pTa) papillary lesions. TCC is associated with a high rate of recurrence (75% after 5 years), and a distinct rate (10%–30%) of progression to HG lesions (grade III), carcinoma in situ, or invasive (IN, pT1). The UroVysion Bladder Cancer Kit (UroVysion Kit) is a US Food and Drug Administration-approved fluorescence in situ hybridization (FISH) probe set for use in the detection of recurrent urothelial carcinoma and in patients with hematuria. It is a multi-target multi-color assay designed to detect aneuploidies for chromosomes 3, 7, 17, and loss of the 9p21 locus in urine specimens. In this study we applied the UroVysion test on freshly isolated interphase nuclei and paraffin-embedded tissue from 22 TCCs (9 HGIN, 3 HGNI, 1 LGIN, 9 LGNI), in order to compare numerical aberrations in the two cell samples from the same tumor. 100 morphologically abnormal nuclei were considered for each sample in both tests, recording hybridization signals corresponding to each probe. The signals were divided according to loss (number of signals/cell < 2), disomy (number of signals/cell = 2), and gain (number of signals/cell > 3). Although the number of samples is low, we observed a general heterogeneity in the copy number changes, also among samples with the same histotype and, surprisingly, within the same sample comparing the two tests carried out. In particular, in the HGIN and LGNI tumors we found differences in copy numbers of chromosomes 3, 7, and 17 (p < 0.01) in 67%–89% of samples; for the 9p21 locus the differences were less significant. Our data provide further evidence for the intra-tumor heterogeneity present in different subpopulations of the same tumor, with interesting insights for diagnostic purposes.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
